Covaxin, Bharat Biotech's COVID-19 Vaccine's Phase 2 Data In Lancet Magazine, It Says ‘It Is Safe, Induces Immune Response With No Severe Effects’

Team Latestly Mar 10, 2021 03:56 PM IST

Leading UK medical journal The Lancet on March 9 said that indigenously developed Covaxin was found to be safe & has demonstrated better performance in the Phase 2 trials compared to Phase 1. The report said that the vaccine developed by Hyderabad-based Bharat Biotech showed better reactogenicity & safety outcomes & enhanced humoral & cell-mediated immune responses compared with the Phase 1 trials. It comes just days after Bharat Biotech and Indian Council of Medical Research (ICMR) announced that Covaxin demonstrated nearly 81% efficacy in interim Phase 3 trials. The paper said that the most common adverse event in the phase 2 trial was pain at the injection site, followed by headache, fatigue, and fever. Watch the video to know more.

(The above story first appeared on LatestLY on Mar 10, 2021 03:56 PM IST. For more news and updates on politics, world, sports, entertainment and lifestyle, log on to our website latestly.com).

Tags

Bharat Biotech COVAXIN COVID-19 Vaccine Hyderabad Indian Council of Medical Research Lancet Magazine UK medical journal

Follow us on News

You Might Also Like

Formula E Race Case: Days After Telangana Cabinet Gives Nod to ACB To Initiate Action Against KT Rama Rao, BRS Leader Says ‘Ready To Face It Legally’

‘Pushpa 2 The Rule’ Premiere Stampede: 8-Year-Old Boy on Ventilator, Netizens Condemn Allu Arjun for Celebrating After Hyderabad Jail Release

Allu Arjun’s Wife Sneha Reddy Breaks Down in Tears as ‘Pushpa 2’ Star Returns Home From Hyderabad Central Jail (Watch Video)

‘Will Gods Be Arrested for Kumbh Mela Stampede?’: Ram Gopal Varma Questions After Allu Arjun’s Arrest Following ‘Pushpa 2’ Premiere Stampede Incident

Categories